CONGRESSES
CONGRESSES
Find information on previous and upcoming congresses
View upcoming congresses and filter through abstracts, presentations, and posters from past congresses.
Upcoming congresses
European Academy of Allergy and Clinical Immunology (EAACI) Congress
BioCryst will attend the 2026 European Academy of Allergy and Clinical Immunology (EAACI) Congress from June 12 – June 15, 2026.
Visit the Congress Website for More Information
Pennsylvania Allergy and Asthma Association
BioCryst will attend the 2026 Pennsylvania Allergy and Asthma Association from June 26 – June 28, 2026.
Browse our archive of congress materials
Filter
Showing 139 Materials
-
Clinical Outcomes With Navenibart According to Baseline Attack Rate, Body Mass Index, and Age: Results of the ALPHA-STAR Trial
EAACI | 2026 | HAE -
Hereditary Angioedema Attack Frequency and Severity According to Individuals Taking Berotralstat for Long-Term Prophylaxis
EAACI | 2026 | HAE -
Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilising Professional Care in Paediatric Patients Aged 2 to <12 years: APeX-P Results Through 48 Weeks
EAACI | 2026 | HAE -
Reductions in Healthcare Resource Utilization in Adolescents with Hereditary Angioedema on Berotralstat
EAACI | 2026 | HAE -
Hereditary Angioedema Attack Rates among Patients with Normal C1 Esterase Inhibitor Before and After Switching from Another Long-Term Prophylaxis to Berotralstat
EAACI | 2026 | HAE -
Reductions in Hereditary Angioedema Attacks among Patients with C1 Esterase Inhibitor Deficiency who Switched from Another Long-Term Prophylaxis to Berotralstat
EAACI | 2026 | HAE -
Real-World Patient Characterization, Prior Long-Term Prophylactic Prescribing Patterns, and Treatment Outcomes for Adults on Berotralstat With Hereditary Angioedema in Japan
EAACI | 2026 | HAE -
Safety, Tolerability, Immunogenicity, and Pharmacokinetics of BCX17725: Single and Multiple Ascending Dose
SID | 2026 | NS -
Preclinical Characterization of BCX17725, a Potent Inhibitor of KLK5 and KLK14, for the Treatment of Netherton Syndrome
SID | 2026 | NS -
Long-Term, Sustained, Robust Hereditary Angioedema Attack Suppression with Navenibart Administered Every 3 and 6 Months: ALPHA-SOLAR Interim Results
AAAAI | 2026 | HAE